💨 Abstract

The U.S. approved Moderna's new COVID-19 vaccine, mNexspike, on May 31, 2025. Designed as a second option, it uses a lower dose and is approved for adults 65+ and high-risk individuals aged 12-64. trials show it matches or exceeds the effectiveness of the prior vaccine, Spikevax. Availability for both vaccines is expected to begin this fall.

Courtesy: WTOP Staff